The use of molecules to inhibit elements of the NF-κB signaling pathway has also been suggested as a therapeutic option for neurological disorders such as [56] multiple sclerosis, Parkinson’s disease [57], Alzheimer’s disease [58], and spontaneous intracerebral hemorrhage [38]. The gene discussed is NFKB1; the disease is multiple sclerosis.